Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus ...
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...
Background The aim of the study was to estimate the sex-specific prevalence and incidence of atrial fibrillation or flutter ...
Genentech, a member of Roche (RHHBY), presented new data for Ocrevus and the investigational Bruton’s tyrosine kinase inhibitor fenebrutinib at ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
Higher intake of ultra-processed foods (UPFs) may exacerbate disease activity in early multiple sclerosis (MS), according to new research presented at the 41st Congress of the European Committee for ...
Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st ...
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosisParis, September 22, 2025. The US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback